asprin

ApprovedSmall molecule

RRoyan Institute

asprin is one of 82 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Coronary Artery BypassActive, not recruiting

Solid TumorsNot yet recruiting

Coronary Artery DiseaseApproved

Active, not recruiting

Coronary Artery BypassApproved

Active, not recruiting

Solid TumorsPhase 2

Not yet recruiting

Competition

Competitive Landscape

223 competitors in Coronary Artery Disease

#DrugCompanyPhaseTrials

Colcrys

Alnylam Pharmaceuticals

Phase 3

4 2

Vanrafia

Novartis

Phase 3

1 3

Byetta

Zetia

1 5

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 3

1 6

Kynamro

KKastle Therapeutics, LLC

Phase 3

1 7

asprin

RRoyan Institute

Approved

1 8

Quercetin

Praluent

3 10

Repatha

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Solid Tumors

NCT07661459

Clinical

Trials by Indication[1]

Coronary Artery Bypass1 trial

A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting

Completed·—·Phase 4·NCT02330640·137 enrolled

Coronary Artery Disease1 trial

Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.

Withdrawn·NNeil Kleiman, MD·Phase 4·NCT01011257

Pregnancy1 trial

The Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy

Completed·RRoyan Institute·Phase 3·NCT01633528·60 enrolled

Solid Tumors1 trial

Optimizing Ancillary Therapies (Acetaminophen, Cannabis, Antihistamines, and NSAIDS) With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

Not yet recruiting·VVal Adams·Phase 2·NCT07661459·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for asprin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — asprin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for asprin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Royan Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: RRoyan Institute

asprin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Coronary Artery Bypass1 trial

Coronary Artery Disease1 trial

Pregnancy1 trial

Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News